Key Highlights: Implications: The acquisition marks a strategic shift for HRV Pharma from API-focused operations into finished formulations and clinical trial supply, diversifying its revenue streams. Phatebo’s established German licensing, distribution infrastructure and global pharmaceutical relationships could strengthen HRV’s access to European markets and expand its contract services portfolio. The deal also positions HRV to...
As advanced therapies, affordable generics, and a growing understanding of obesity reshape treatment, India is emerging as a promising market for the next generation of metabolic healthcare. Obesity is no longer viewed simply as a matter of body weight. Increasingly recognized as a complex, chronic health condition, it is reshaping conversations around preventive healthcare, metabolic...
As pharmaceutical supply chains evolve, India has an opportunity to transform its reliance on imported active pharmaceutical ingredients into a new era of manufacturing leadership, scientific innovation, and global supply chain resilience. Every medicine begins with a molecule that makes treatment possible. Behind every tablet, capsule, injection, or complex therapy lies an essential component that...
Executive Summary Mounjaro, a diabetes and weight-loss injection that reached India only in 2025, is now the country’s best-selling brand, with ₹923 crore in sales in the 12 months to March 2026. Right behind it is a lineup of old favourites: antibiotics, diabetes pills, inhalers, acid-suppressants and painkillers that doctors have prescribed for years. Together,...
Executive Summary India has emerged as a major force in the global pharmaceutical industry, supported by its extensive manufacturing infrastructure, technical expertise and strong presence across international markets. Active Pharmaceutical Ingredients (APIs) remain a critical component of this ecosystem, enabling the production of medicines across a wide range of therapeutic areas. Indian manufacturers have developed...
Key Highlights: Implications: Nucelion and VeGen Bio’s partnership could strengthen India’s domestic CAR-T manufacturing ecosystem by combining dual-target therapy development with GMP production capabilities. VL-2511’s BCMA/CD19 approach may help address antigen escape in multiple myeloma, while localized manufacturing could improve affordability and access. Clinical validation, scalability and regulatory compliance will determine its competitive potential. Source:...
Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and active psoriatic arthritis who failed other DMARDs, with manufacturing at its Bachupally biologics facility and supply support from Gland Pharma. The approval is conditional on a Phase IV study (protocol due within 3...
